Email this article A comprehensive assessment of metabolic parameters in obese patients on xenical
- Authors: Ametov AS1, Demidova TY.1, Tselikovskaya AL1
-
Affiliations:
- РМАПО
- Issue: Vol 79, No 1 (2004)
- Pages: 49-53
- Section: Editorial
- URL: https://bakhtiniada.ru/0040-3660/article/view/29764
- ID: 29764
Cite item
Full Text
Abstract
Aim. To study effects ofxenical combined with moderately hypocaloric diet on fat tissue mass, carbohydrate and lipid metabolism in patients with metabolic syndrome.
Material and methods. The study included 60 patients with body mass index (BMI) over 30 kg/m2, mild and moderate arterial hypertension, dyslipidemia, impaired glucose tolerance (IGT) and diabetes mellitus (DM) type 2. The patients were divided into two groups. 30 patients of group 1 received xenicaf® in a dose 120 mg 3 times a day for 24 weeks. 30 patients of the control group received only the above diet for 24 weeks. The examination included 24-h monitoring of arterial pressure, anthropometric measurements, tests for glycemia, C-peptide, cholesterol, triglycerides (TG), LDLP, HDLP. Results. Group 1 patients reduced their weight by 10.8 + 7.5 kg and fat tissue mass by 9.4 ± 9.2 kg. This was in correlation with improvement of fatty, carbohydrate metabolism, arterial pressure. After 24 weeks of therapy xenical lowered cholesterol by 15%, LDLP cholesterol by 20%, TG by 28%, systolic and diastolic pressure by 5 and 4%.
Conclusion. Combination ofxenical with hypocaloric diet can be used in therapy of patients with metabolic syndrome.
Material and methods. The study included 60 patients with body mass index (BMI) over 30 kg/m2, mild and moderate arterial hypertension, dyslipidemia, impaired glucose tolerance (IGT) and diabetes mellitus (DM) type 2. The patients were divided into two groups. 30 patients of group 1 received xenicaf® in a dose 120 mg 3 times a day for 24 weeks. 30 patients of the control group received only the above diet for 24 weeks. The examination included 24-h monitoring of arterial pressure, anthropometric measurements, tests for glycemia, C-peptide, cholesterol, triglycerides (TG), LDLP, HDLP. Results. Group 1 patients reduced their weight by 10.8 + 7.5 kg and fat tissue mass by 9.4 ± 9.2 kg. This was in correlation with improvement of fatty, carbohydrate metabolism, arterial pressure. After 24 weeks of therapy xenical lowered cholesterol by 15%, LDLP cholesterol by 20%, TG by 28%, systolic and diastolic pressure by 5 and 4%.
Conclusion. Combination ofxenical with hypocaloric diet can be used in therapy of patients with metabolic syndrome.
Keywords
About the authors
A S Ametov
РМАПОМосква; РМАПО
T Yu Demidova
РМАПОМосква; РМАПО
A L Tselikovskaya
РМАПОМосква; РМАПО
References
- Аметов А. С., Демидова Т. Ю., Целиковская А. Я. Ожирение и сердечно-сосудистые заболевания. Тер. арх. 2001; 66-69.
- Аметов А. С., Демидова Т. Ю., Пархонина Е. С. Ожирение - основа метаболического синдрома. Лечащий врач 2001; 5: 28-32.
- Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. Рус. мед. журн. 2000; 9: 56-60.
- Hodge A. M., Boyko E. J., de Courten M. et al. Leptin and other components of the Metabolic Syndrome in Mauritius-a factor analysis. Int. J. Obes. Relat. Metab. Disord. 2001; 25 (suppi. 1): 126-131/
- Sorensen T. I., Echwald S., Holm J. С. Leptin in obesity. Br. Med. J. 1996; 313: 953-954/
- Аметов А. С., Демидова Т. Ю., Целиковская А. Л. Влияние лептина на регуляцию массы тела. Сердечная недостаточность. 2001; 3: 135-137.
- Reaven G. M. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density particles. J. Clin. Invest. 1993; 92: 141-146.
- Reaven G. M. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia 1994; 37: 948- 952.
- Arvaniti K., Ricquier D., Champigny O., Richard D. Leptin and corticosterone have opposite effects on food intake and the expression of UCP1 mRNA in brown adipose tissue of lep(ob)/ lep(ob) mice. Endocrinology 1998; 139 (suppl. 9): 4000-4003.
- Bryson J. M. The future of leptin and leptin analogues in the treatment of obesity. Diabet. Obes. Metab. 2000; 2 (suppl. 2): 83-89.
- Cam J. F., Kolaczynski J. W. Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455-1462.
- Hotamisgilil С. S., Arner P., Caro J. F. et al. Increased adipose tissue expression of tumor necrosis factor in a human obesity and insulin resistance. J. Clin. Invest. 1995; 95: 1409-1415.
- Hotamisgilil С. S., Shargill N. S., Spiegelman В. М. Adipose expression of tumor necrosis factor-a: direct role in obesitylinked insulin resistance. Science 1993; 259: 87-91.
- Soma S. C., Yamamoto M. T. et al. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-a: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 1998; 47: 691-695.
- Goldstein D. J. Beneficial health effects of modest weight loss. Int. J. Obesity 1992; 16: 397-415.
- Lean M. E., Han T. S. Impairment of health and quality of life in people with large waist circumference. Lancet 1998; 351: 853-856.
- Зимин Ю. В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома X. Кардиология 1998; 6: 71-81.
Supplementary files
